Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead Sciences, seeing a 22% boost, benefited from regulatory wins in treatments for liver disease and HIV. The company’s ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

42% of patients achieved complete remission within three months and the median duration of response was 14.1 months, the company noted in its release. While Gilead’s Tecartus and Novartis’ Kymriah ...